Detalhe da pesquisa
1.
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(1): 58-65, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31493537
2.
Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(11): 2040-2046, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32712326
3.
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease.
Biol Blood Marrow Transplant
; 26(2): 323-332, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31618690
4.
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
Biol Blood Marrow Transplant
; 24(4): 871-876, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29288818
5.
Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 24(1): 142-149, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28951193
6.
Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 24(1): 133-141, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28870777
7.
T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies.
Biol Blood Marrow Transplant
; 23(10): 1685-1694, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28734876
8.
Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 23(1): 67-74, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27789361
9.
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Biol Blood Marrow Transplant
; 23(12): 2088-2095, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28711727
10.
Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.
Biol Blood Marrow Transplant
; 23(3): 452-458, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28017734
11.
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies.
Biol Blood Marrow Transplant
; 23(11): 2004-2011, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28733264
12.
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.
Biol Blood Marrow Transplant
; 22(2): 258-267, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26325439
13.
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Blood
; 124(6): 899-906, 2014 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24963043
14.
Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.
Biol Blood Marrow Transplant
; 21(9): 1663-78, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26028505
15.
High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.
Biol Blood Marrow Transplant
; 21(11): 1985-93, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26238810
16.
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Biol Blood Marrow Transplant
; 21(12): 2039-2051, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26428082
17.
WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.
Blood
; 121(2): 308-17, 2013 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23160468
18.
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
Biol Blood Marrow Transplant
; 20(3): 354-60, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24315843
19.
Targeting WT1 in hematologic malignancies?
Blood
; 130(18): 1959-1960, 2017 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29097369
20.
Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation.
Blood
; 120(24): 4882-91, 2012 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23012326